UB Paderborn / Katalog / Suche / in CDI

Use of poxvirus display to select antibodies specific for complex membrane antigens

mAbs, 2023-12, Vol.15 (1), p.2249947-2249947

2023

Volltextzugriff (PDF)

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

Journal of neuroinflammation, 2022-08, Vol.19 (1), p.1-200, Article 200

2022

Volltextzugriff (PDF)

Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model

International journal of molecular sciences, 2021-09, Vol.22 (17), p.9465

2021

Volltextzugriff (PDF)

Glucoraphanin and 4-Hydroxyglucobrassicin Contents in Seeds of 59 Cultivars of Broccoli, Raab, Kohlrabi, Radish, Cauliflower, Brussels Sprouts, Kale, and Cabbage

Journal of agricultural and food chemistry, 2004-02, Vol.52 (4), p.916-926

2004

Volltextzugriff (PDF)

Generation and preclinical characterization of an antibody specific for SEMA4D

mAbs, 2016-01, Vol.8 (1), p.150-162

2016

Volltextzugriff (PDF)

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other

Alzheimer's & dementia, 2020-12, Vol.16 (S9)

2020

Volltextzugriff (PDF)

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

VX15 ANTI-SEMAPHORIN 4D ANTIBODY (PEPINEMAB) INCREASES FDG-PET SIGNAL AND IS A POTENTIAL TREATMENT FOR ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P926-P927

2019

Volltextzugriff (PDF)

P3‐007: VX15 ANTI‐SEMAPHORIN 4D ANTIBODY (PEPINEMAB) INCREASES FDG‐PET SIGNAL AND IS A POTENTIAL TREATMENT FOR ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_17), p.P926-P927

2019

Volltextzugriff (PDF)

Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1545-1545

2019

Volltextzugriff (PDF)

The Role of Advanced Practice Clinicians in the Availability of Abortion Services in the United States

Journal of obstetric, gynecologic, and neonatal nursing, 2007-09, Vol.36 (5), p.471-476

2007

Volltextzugriff (PDF)

Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases

Annals of surgery, 2003-10, Vol.238 (4), p.538-550

2003

Volltextzugriff (PDF)

Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B199-B199

2018

Volltextzugriff (PDF)

Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3661-3661

2017

Volltextzugriff (PDF)

Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1762-1762

2018

Volltextzugriff (PDF)

Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4888-4888

2016

Volltextzugriff (PDF)

Development of anti-CXCL13 monoclonal antibody for the treatment of autoimmune and immuno-oncological disorders (THER2P.950)

The Journal of immunology (1950), 2015-05, Vol.194 (1_Supplement), p.67-67.1

2015

Volltextzugriff (PDF)

Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies

Cancer immunology research, 2018-09, Vol.6 (9_Supplement), p.PR09-PR09

2018

Volltextzugriff (PDF)

Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy

Cancer immunology research, 2019-02, Vol.7 (2_Supplement), p.PR10-PR10

2019

Volltextzugriff (PDF)

Abstract 5030: Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5030-5030

2014

Volltextzugriff (PDF)

Abstract 1245: Reduction of tumor growth and metastasis by a humanized IgG4 monoclonal antibody to SEMA4D (VX15/2503)

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1245-1245

2013

Volltextzugriff (PDF)

In Response to Letter: On risks of abortion

Journal of obstetric, gynecologic, and neonatal nursing, 2008-03, Vol.37 (2), p.125-125

2008

Volltextzugriff (PDF)

Abstract B023: Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.B023-B023

2016

Volltextzugriff (PDF)

Abstract A119: Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates immune-mediated tumor rejection

Cancer immunology research, 2016-01, Vol.4 (1_Supplement), p.A119-A119

2016

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Use of poxvirus display to select antibodies specific for complex membrane antigens

Use of poxvirus display to select antibodies specific for complex membrane antigens

Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity

Anti-Semaphorin 4D Rescues Motor, Cognitive, and Respiratory Phenotypes in a Rett Syndrome Mouse Model

Glucoraphanin and 4-Hydroxyglucobrassicin Contents in Seeds of 59 Cultivars of Broccoli, Raab, Kohlrabi, Radish, Cauliflower, Brussels Sprouts, Kale, and Cabbage

Generation and preclinical characterization of an antibody specific for SEMA4D

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD

VX15 ANTI-SEMAPHORIN 4D ANTIBODY (PEPINEMAB) INCREASES FDG-PET SIGNAL AND IS A POTENTIAL TREATMENT FOR ALZHEIMER’S DISEASE

P3‐007: VX15 ANTI‐SEMAPHORIN 4D ANTIBODY (PEPINEMAB) INCREASES FDG‐PET SIGNAL AND IS A POTENTIAL TREATMENT FOR ALZHEIMER'S DISEASE

Abstract 1545: Altered myeloid and lymphoid composition of tumor microenvironment following anti-SEMA4D and immune checkpoint combination therapies

The Role of Advanced Practice Clinicians in the Availability of Abortion Services in the United States

Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases

Abstract B199: Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy

Abstract 3661: Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies

Abstract 1762: Shifting the tumor microenvironment with first-in-class semaphorin 4D mab for combination immunotherapy

Abstract 4888: Antibody blockade of semaphorin 4D breaks down stromal barriers to enhance tumoricidal immune infiltration, supporting rational immunotherapy combinations

Development of anti-CXCL13 monoclonal antibody for the treatment of autoimmune and immuno-oncological disorders (THER2P.950)

Abstract PR09: Breaking down barriers restricting myeloid cell differentiation and infiltration in the tumor microenvironment with a first-in-class antibody targeting semaphorin4D, and rational combination therapies

Abstract PR10: Reprogramming myeloid cells in TME with pepinemab, first-in-class semaphorin 4D MAb, enhances combination immunotherapy

Abstract 5030: Antibody blockade of Semaphorin 4D promotes tumor rejection and improves response to immune checkpoint blockade and chemotherapy

Abstract 1245: Reduction of tumor growth and metastasis by a humanized IgG4 monoclonal antibody to SEMA4D (VX15/2503)

In Response to Letter: On risks of abortion

Abstract B023: Antibody blockade of Semaphorin 4D enhances infiltration of APC and CD8 T cells and reduces immune suppression to facilitate immune-mediated tumor rejection

Abstract A119: Antibody blockade of Semaphorin 4D neutralizes barrier to immune infiltration and facilitates immune-mediated tumor rejection

Suchergebnisse filtern